Skip to main content

Home/ health information/ Group items tagged UK-pharmacy-survey

Rss Feed Group items tagged

pharmacybiz

Unveiling the UKHSA and ONS Winter COVID-19 Study - 0 views

  •  
    The UK Health Security Agency (UKHSA) and the Office for National Statistics (ONS) will jointly launch a new study to gather data on COVID-19 this winter. The Winter COVID-19 Infection Study (WCIS) will run from November 2023 to March 2024, involving up to 200,000 participants, UKHSA has said on Monday (October 2). UKHSA previously commissioned the Coronavirus Infection Survey (CIS), conducted by the ONS in collaboration with scientific study leaders from Oxford University, analysing more than 11.5 million swab tests and 3 million blood tests from April 2020 to March 2023. Meanwhile, the Winter CIS study involves conducting up to 32,000 lateral flow tests weekly, providing vital insights into COVID-19 prevalence in the broader community. The sample will be structured to broadly reflect key population characteristics.
pharmacybiz

World Mental Health Day: Tips to combat workplace stress - 0 views

  •  
    The mental health challenges faced by pharmacists are a significant concern that is frequently discussed within the industry today. The Royal Pharmaceutical Society's (RPS) fifth annual workforce wellbeing survey indicated that 86% of pharmacists are at a high risk of burnout. Key factors contributing to this burnout include inadequate staffing, poor work-life balance, and extended working hours. Mental Health UK also identifies burnout as one of the most pressing issues affecting modern workplaces. According to the charity's Burnout Report released in January 2024, 9 in 10 adults in the UK reported experiencing high or extreme stress in the past year. The charity warns that burnout may increase the risk of developing mental health conditions such as depression or anxiety, underscoring the need for serious attention. Today, on World Mental Health Day, we reflect on the theme, "It is time to prioritise mental health in the workplace."
pharmacybiz

Pharmaceutical Sector Leads in R&D Investment | Latest Industry News 2024 - 0 views

  •  
    UK businesses invested £50 billion in research and development (R&D) in 2023, according to the annual survey report released by the Office for National Statistics (ONS). This marks a £1.4 billion increase (2.9%) compared to the previous year's £48.5 billion. Pharmaceuticals remained the largest contributor to business R&D spending, with £8.7 billion allocated to the sector, accounting for 17.4% of the total R&D expenditure by UK businesses. However, this is slightly down from £8.8 billion in 2022. Other major contributors among product groups included software development with R&D spending at £7.6 billion, and miscellaneous business activities such as technical testing and analysis at £6.9 billion. When measuring the value of R&D performed by industry, the scientific research and development industry emerged as the top performer, with £12.7 billion spent, representing 25.3% of total business R&D.
pharmacybiz

Nexium Control's Insights on Heartburn Trends - 0 views

  •  
    Nexium Control, the UK's number one selling heartburn product for 24-hour protection1, has commissioned research to explore consumer attitudes to heartburn awareness of the different products on the market in Great Britain and Ireland (1,500 UK and 500 IE respondents). The research found that 53% of respondents usually opt for short-acting treatments to heartburn2, despite longer-acting products being able to provide relief over a 24-hour period. The research from Nexium Control revealed that 54% of people surveyed wished there was a product that managed symptoms for longer3, with 55% of respondents agreeing that short-acting treatments only last a maximum of five hours4. To help their patients understand there are longer-acting options available, pharmacists can provide information and guidance on treatments, such as proton pump inhibitors like Nexium Control. Shorter-acting products, which shoppers often reach for, work by either neutralising the acid already in the stomach or by forming a layer that floats to the top of the stomach, stopping acid rising into the food pipe. Double action treatments which utilise both methods are also available. Containing esomeprazole, Nexium Control reduces the production of stomach acid for up to 24-hour protection with just one pill, treating the cause and symptoms of heartburn - allowing time for the oesophagus to recover from the acid irritation.
pharmacybiz

Retail Crime Update 2024 | UK to Introduce Stand-Alone Offence for Assaulting Shop Workers - 0 views

  •  
    During a debate on Thursday (5) members of the House of Lords voiced unanimous concern over the alarming rise in retail crime and its impact on businesses, workers, and communities. Lord Hannett of Everton (Labour), former General Secretary of the Union of Shop, Distributive and Allied Workers (USDAW), initiated the debate, citing alarming statistics from the Office for National Statistics (ONS). The ONS figures showed that nearly 470,000 shoplifting offences were recorded across England and Wales in the year leading up to October 2024- a 29 per cent increase and the highest figure since records started in March 2003. Lord Hannett highlighted widespread underreporting of retail crime, noting "many retail workers do not report incidents because they simply do not believe that anything will happen when they do." He pointed to a British Retail Consortium survey revealing over 1,300 incidents of violence and abuse against retail workers daily in 2022-2023, with only a third reported to the police and fewer than 8 per cent leading to prosecutions.
pharmacybiz

Prescription Charges Crisis: Urgent Plea to DHSC for a Freeze in 2024-2025 - 0 views

  •  
    Campaigners have submitted an open letter to the Department of Health and Social Care (DHSC), urging the Minister for Primary Care and Public Health to freeze prescription charges to keep people with long-term conditions alive and well. The campaign is led by the Prescription Charges Coalition, which represents over 50 organisations, including Royal Pharmaceutical Society (RPS) and Pharmacists' Defence Association (PDA). Currently, the prescription charge is £9.65 per item, and campaigners have asked the government to freeze it for 2024 and 2025 as people living with long-term health conditions in England are "being forced to choose between heating, eating, and taking their vital medication on a daily basis." In 2023, a study conducted by the Prescription Charges Coalition revealed that almost 10 per cent of survey participants had skipped medication in the previous year due to the cost of prescriptions. This led to increased physical and mental health problems, as well as impacted the time they took off work. Laura Cockram, Chair of the Prescription Charges Coalition and Head of Campaigns at Parkinson's UK, expressed deep concern that a further rise in the charge this year will lead to people skipping or not taking the full dose of their medication, which will affect their health and put more pressure on the already under pressure NHS.
pharmacybiz

NHS Digital Shift 2024 : Public Trust in Data Sharing for AI Yet Hesitant on Care Robots - 0 views

  •  
    Transitioning from analogue to digital is one of three major "shifts" the government has deemed essential for the future of the NHS. These shifts, with the other two being the moving from hospital to community care and from sickness to prevention, will also form the foundation of the 10-Year Health Plan. The question is: are the public ready to embrace this digital transformation, which would involve sharing their health data for the development of artificial intelligence (AI) systems within the NHS? Results from a UK-wide poll show that the majority of people (75 per cent) are willing to share some of their health data for AI development. The survey commissioned by the Health Foundation included more than 7,000 members of the public (aged 16 years and older). Nearly 60 per cent expressed willingness to share information about their eye health, with 58 per cent open to sharing details about the medications they are taking, and 57 per cent willing to disclose any long-term illnesses they live with.
pharmacybiz

BGMA Support: Innovating Pharma Scheme | UK - 0 views

  •  
    The British Generic Manufacturers Association has backed the UK government's proposed changes to the Statutory Scheme for branded medicines, which includes a 'Life Cycle Adjustment' (LCA) mechanism to permit a lower rebate rate for medicines sold in competitive markets. The association underscored the necessity for crucial amendments to forestall unintended consequences and ensure a practical alignment with market operations. A precisely tailored approach is crucial in ensuring sustainability and growth in this sector, the BGMA said in a statement on Oct. 11. The Department of Health and Social Care is currently working on the successor to the 2019 voluntary scheme for branded medicines and pricing access (VPAS) agreement, slated to end in 2023. Negotiations for this successor, scheduled to begin on January 1, 2024, are already underway. "We are pleased that the Statutory Scheme consultation recognises that branded generic and biosimilar medicines are subject to different market dynamics and competitive pressures," said Mark Samuels, Chief Executive of BGMA. "As such, a one-size-fits-all approach across all branded products is not suitable for the next five years. It is crucial to adopt a precisely tailored approach to this sector, ensuring both sustainability and growth."
« First ‹ Previous 81 - 88 of 88
Showing 20 items per page